Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia: A Retrospective Case Series



Forgot your login? GET HELP

Objective: To demonstrate how effectively aripiprazole can be utilized to manage antipsychotic-induced hyperprolactinemia.

Methods: The files of 3 female patients with a history of psychotic illness and hyperprolactinemia who were treated at a state hospital between February 2018 and May 2019 were retrospectively analyzed. All were found to have elevated prolactin levels and underwent treatment with aripiprazole in addition to their concomitant medications.

Results: In general, the addition of aripiprazole to the treatment regimen of each of the patients corresponded to a decline in their serum prolactin levels.

Conclusions: Hyperprolactinemia is frequently observed in patients treated with antipsychotic medications. Low-dose treatment with aripiprazole may offer a relatively rapid relief from sustained hyperprolactinemia and associated adverse effects even after a long-acting injectable is discontinued.

Prim Care Companion CNS Disord 2020;22(1):19br02536